Researchers investigating ways to reduce exhaustion in cancer-fighting T-cells found that the Golgi apparatus can be used as a simple marker -- more Golgi means a more robust cell.

AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by immunology competition and risks.

Type 2 diabetes (T2D) and obesity (OB) are associated with chronic low-grade inflammation and increased fracture risk. In vitro studies showed that inflammation induces bone erosion and inhibits bone ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of ...

New research from the University of Pittsburgh uncovers how inhaled house dust mites, a common trigger of allergic asthma, ...

The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...

The disease involves the activation of Th2 helper T cells and cytokines produced by these cells, including IL-4, IL-5 and IL-13. The researchers utilized a Fra-2 transgenic mouse model that ...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...